Advancing Stroke Safety and Efficacy Through Early Tirofiban Administration After Intravenous Thrombolysis (ASSET-IT)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 832 participants.
Also called NCT06134622
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 832 participants
- Registry
-
NCT06134622
-
- Other papers using this trial's data
- Early Tirofiban Infusion after Intravenous Thrombolysis for Stroke
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT06134622. Randomized; quadruple masking; primary purpose treatment. Start 2024-03-14 (actual); primary completion 2024-09-25 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Advancing Stroke Safety and Efficacy Through Early Tirofiban Administration After Intravenous Thrombolysis (ASSET-IT)
- Acronym
- ASSET-IT
- Condition
- Acute Ischemic Stroke
- Intervention (Drug)
- Intravenous thrombolysis plus tirofiban
- Intervention (Drug)
- Intravenous thrombolysis plus placebo
- Lead sponsor
- The First Affiliated Hospital of University of Science and Technology of China
Record details
- Record id
cardio:ct-nct06134622- Content hash
53783fa7d8104d2289e81df453750ae0206a3fac7665468710bf6ba5a0d96acd